Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

The Informed-Consent Gap

What men are often not told before starting

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (guidance)

Reference only. Not medical advice.

What can go wrong

Without full disclosure, men make an irreversible-feeling decision (fertility loss, dependency) on incomplete information, the core ethical failure documented in DTC testosterone reporting.

This is something to take to a clinician. The Atlas can tell you what is known about the informed-consent gap in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

A recurring theme in investigative reporting and the 2025 JAMA work on direct-to-consumer testosterone is an informed-consent gap: men start TRT without being clearly told three things. First, it suppresses sperm production, often dramatically, and recovery is not guaranteed, a problem if children are wanted. Second, it is usually not a short course but a long-term or lifelong dependency, because the body's own production is suppressed and may not fully recover. Third, it requires ongoing monitoring (hematocrit especially) that some platforms do not reliably provide. Genuine informed consent covers all three before the first prescription.

The three things many men only learn after starting: fertility, permanence, and monitoring.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • What real informed consent should cover

What people get wrong

  • Often saidTRT is an easy thing to try and stop

    ActuallyIt suppresses your own production and fertility, and stopping after long use can leave you hypogonadal until (and unless) the axis recovers. It is closer to a chronic medication than a trial.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Often omitted
Fertility suppression
Often omitted
The lifelong-commitment reality
Often omitted
The monitoring requirement

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about The Informed-Consent Gap. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • JAMA DTC testosterone investigation2025

    Found some direct-to-consumer platforms did not adequately convey treatment risks before prescribing